Please enable Javascript
teclistamab
Bispecific Antibody Treatment Leads to ‘Deep and Durable’ Responses in R/R MM
Cecilia Brown
Myeloma
|
November 22, 2022
Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable...
Read More
Teclistamab Plus Daratumumab Shows Improved Clinical Efficacy in Pretreated Multiple Myeloma
Leah Sherwood
Myeloma
|
November 16, 2022
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Read More
Advertisement
Advertisement
Advertisement